AI assistant
JUBILANT PHARMOVA LIMITED — Call Transcript 2019
Jul 19, 2019
62021_rns_2019-07-19_fab1bf5b-b417-48ac-b188-8f5c602683d7.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [183 x 142] intentionally omitted <==
July 19, 2019
BSE Limited National Stock Exchange of India Limited P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051
Dear Sirs,
Sub.: Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Unaudited Financial Results for the quarter ended June 30, 2019
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on July 26, 2019 after submission of the financial results for the quarter ended June 30, 2019 to the Stock Exchanges. Details of the Conference Call are attached.
This is for information and record.
Thanking you,
Yours faithfully,
For Jubilant Life Sciences Limited
RAJIV Digitally signed by RAJIV SHAH Date: 2019.07.19 SHAH 11:53:17 +05'30' Rajiv Shah Company Secretary
Encl.: as above
==> picture [581 x 130] intentionally omitted <==
==> picture [89 x 70] intentionally omitted <==
Jubilant Life Sciences Limited 1A, Sector 16A, Noida 201301, India Tel. : +91 120 4361000 www.jubl.com
Noida, Friday July 19, 2019
Conference call on Friday, July 26, 2019 at 05:00 pm IST
The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host Q1’FY20 Earnings Conference Call for analysts and investors on Friday, July 26, 2019 at 05:00 pm IST. The call will commence with a brief management discussion on the financial performance for the quarter ended June 30[th] , 2019, followed by an interactive Question & Answer session.
| Conference Dial-In Numbers | Conference Dial-In Numbers |
|---|---|
| Universal Access: | + 91 22 6280 1141 + 91 22 7115 8042 |
| Local Access Number: | +91-7045671221 Available all over India. |
| Toll Free Number: | USA:1 866 746 2133 UK:0 808 101 1573 Singapore:800 101 2045 Hong Kong:800 964 448 |
| Pre-registration: | To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call. |
| Replay Facility: | Available from July 26 to August 02, 2019 Dial in No.:+91 22 7194 5757 Playback ID: 90561# |
-ENDS -
1
About Jubilant Life Sciences Limited
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Other businesses including Drug Discovery Solutions and India Branded Pharmaceuticals. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectibles and Non-sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions business, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 2 world class research centers in India. Jubilant Life Sciences Limited has a team of around 7,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com
For more information please contact:
Ravi Agrawal / Vineet Mayer Jubilant Life Sciences Limited Ph: +91-120 4361002 / 1021 E-mail: [email protected] [email protected]
Siddharth Rangnekar / Karl Kolah CDR India Ph: +91-22 6645 1209 / 1220 E-mail: [email protected] [email protected]
Disclaimer: Statements made on the call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
2